Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. (Q50270301)

28 February 2018

title

Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. (English)

1 reference

28 February 2018

pneumococcal conjugate vaccine

main subject

1 reference

Julie M Skinner

1

1 reference

28 February 2018

Lani Indrawati

2

1 reference

28 February 2018

Jayme Cannon

3

1 reference

28 February 2018

Jeffrey Blue

4

1 reference

28 February 2018

Michael Winters

5

1 reference

28 February 2018

John Macnair

6

1 reference

28 February 2018

Narahari Pujar

7

1 reference

28 February 2018

Walter Manger

8

1 reference

28 February 2018

Yuhua Zhang

9

1 reference

28 February 2018

Joseph Antonello

10

1 reference

28 February 2018

John Shiver

11

1 reference

28 February 2018

Michael Caulfield

12

1 reference

28 February 2018

Jon H Heinrichs

13

1 reference

28 February 2018

language of work or name

English

0 references

publication date

1 October 2011

1 reference

28 February 2018

published in

Vaccine

1 reference

28 February 2018

volume

29

1 reference

28 February 2018

page(s)

8870-8876

1 reference

28 February 2018

issue

48

1 reference

28 February 2018

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Genetic basis for the new pneumococcal serotype, 6C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Impact of conjugate pneumococcal vaccines on antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Brief review of the clinical effectiveness of PREVENAR against otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.078

10.1016/J.VACCINE.2011.09.078

7 January 2021

Identifiers

DOI

1 reference

28 February 2018

PubMed ID

21964055

1 reference

28 February 2018